142 related articles for article (PubMed ID: 28892804)
1. Generation of a Potential Prognostic Matrix for Papillary Thyroid Cancer that Assesses Age, Tumor Size, Transforming Growth Factor-β, and BRAFV600E Mutation.
Wang P; Lun Y; Fu Y; Wang F; Zhao S; Wang Y; Hou X
Oncol Res Treat; 2017; 40(10):586-592. PubMed ID: 28892804
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Features and Prognosis of Papillary Thyroid Microcarcinoma for Surgery and Relationships with the BRAFV600E Mutational Status and Expression of Angiogenic Factors.
Shi C; Guo Y; Lv Y; Nanding A; Shi T; Qin H; He J
PLoS One; 2016; 11(12):e0167414. PubMed ID: 27936049
[TBL] [Abstract][Full Text] [Related]
3. Identification of new biomarkers for human papillary thyroid carcinoma employing NanoString analysis.
Chitikova Z; Pusztaszeri M; Makhlouf AM; Berczy M; Delucinge-Vivier C; Triponez F; Meyer P; Philippe J; Dibner C
Oncotarget; 2015 May; 6(13):10978-93. PubMed ID: 25868389
[TBL] [Abstract][Full Text] [Related]
4. The BRAFV600E oncogene induces transforming growth factor beta secretion leading to sodium iodide symporter repression and increased malignancy in thyroid cancer.
Riesco-Eizaguirre G; Rodríguez I; De la Vieja A; Costamagna E; Carrasco N; Nistal M; Santisteban P
Cancer Res; 2009 Nov; 69(21):8317-25. PubMed ID: 19861538
[TBL] [Abstract][Full Text] [Related]
5. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation.
Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX
Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628
[TBL] [Abstract][Full Text] [Related]
6. Uncommon BRAF mutations in the follicular variant of thyroid papillary carcinoma: New insights.
Rossi ED; Martini M; Bizzarro T; Capodimonti S; Cenci T; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM
Cancer Cytopathol; 2015 Oct; 123(10):593-602. PubMed ID: 26230187
[TBL] [Abstract][Full Text] [Related]
7. The role of BRAFV600E mutation and ultrasonography for the surgical management of a thyroid nodule suspicious for papillary thyroid carcinoma on cytology.
Moon HJ; Kwak JY; Kim EK; Choi JR; Hong SW; Kim MJ; Son EJ
Ann Surg Oncol; 2009 Nov; 16(11):3125-31. PubMed ID: 19644722
[TBL] [Abstract][Full Text] [Related]
8. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
9. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
10. BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer.
Romei C; Ciampi R; Faviana P; Agate L; Molinaro E; Bottici V; Basolo F; Miccoli P; Pacini F; Pinchera A; Elisei R
Endocr Relat Cancer; 2008 Jun; 15(2):511-20. PubMed ID: 18509003
[TBL] [Abstract][Full Text] [Related]
11. Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma.
Yoon JH; Han K; Lee E; Lee J; Kim EK; Moon HJ; Park VY; Nam KH; Kwak JY
PLoS One; 2020; 15(2):e0228968. PubMed ID: 32053670
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of the detection of BRAF mutations in thyroid pathology: potential usefulness as diagnostic, prognostic and theragnostic applications.
Lassalle S; Hofman V; Ilie M; Butori C; Bozec A; Santini J; Vielh P; Hofman P
Curr Med Chem; 2010; 17(17):1839-50. PubMed ID: 20345340
[TBL] [Abstract][Full Text] [Related]
13. DNA methylation of MAPK signal-inhibiting genes in papillary thyroid carcinoma.
Lee EK; Chung KW; Yang SK; Park MJ; Min HS; Kim SW; Kang HS
Anticancer Res; 2013 Nov; 33(11):4833-9. PubMed ID: 24222120
[TBL] [Abstract][Full Text] [Related]
14. Occult oncocytic papillary thyroid carcinoma with lymphoid stroma (Warthin-like tumor): report of a case with concomitant mutations of BRAF V600E and V600K.
Han F; Zhang L; Zhang S; Zhou H; Yi X
Int J Clin Exp Pathol; 2015; 8(5):5896-901. PubMed ID: 26191315
[TBL] [Abstract][Full Text] [Related]
15. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.
Liu RT; Chen YJ; Chou FF; Li CL; Wu WL; Tsai PC; Huang CC; Cheng JT
Clin Endocrinol (Oxf); 2005 Oct; 63(4):461-6. PubMed ID: 16181240
[TBL] [Abstract][Full Text] [Related]
16. BRAF V600E mutation analysis increases diagnostic accuracy for papillary thyroid carcinoma in fine-needle aspiration biopsies.
Zatelli MC; Trasforini G; Leoni S; Frigato G; Buratto M; Tagliati F; Rossi R; Cavazzini L; Roti E; degli Uberti EC
Eur J Endocrinol; 2009 Sep; 161(3):467-73. PubMed ID: 19574281
[TBL] [Abstract][Full Text] [Related]
17. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma.
Rossi ED; Martini M; Capodimonti S; Lombardi CP; Pontecorvi A; Vellone VG; Zannoni GF; Larocca LM; Fadda G
Cancer Cytopathol; 2013 Jun; 121(6):291-7. PubMed ID: 23192956
[TBL] [Abstract][Full Text] [Related]
18. A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.
Occhi G; Barollo S; Regazzo D; Bertazza L; Galuppini F; Guzzardo V; Jaffrain-Rea ML; Vianello F; Ciato D; Ceccato F; Watutantrige-Fernando S; Bisognin A; Bortoluzzi S; Pennelli G; Boscaro M; Scaroni C; Mian C
Oncotarget; 2015 Oct; 6(31):32104-14. PubMed ID: 26392334
[TBL] [Abstract][Full Text] [Related]
19. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic.
Sykorova V; Dvorakova S; Ryska A; Vcelak J; Vaclavikova E; Laco J; Kodetova D; Kodet R; Cibula A; Duskova J; Hlobilkova A; Astl J; Vesely D; Betka J; Hoch J; Smutny S; Cap J; Vlcek P; Novak Z; Bendlova B
J Endocrinol Invest; 2010 May; 33(5):318-24. PubMed ID: 20009493
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of lncRNA-ATB by Transforming Growth Factor β1 (TGF-β1) Promotes Migration and Invasion of Papillary Thyroid Carcinoma Cells.
Cui M; Chang Y; Du W; Liu S; Qi J; Luo R; Luo S
Med Sci Monit; 2018 Jul; 24():5152-5158. PubMed ID: 30042377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
